Leading contributors to date include:
- Lyda Hill: $50 million,
- The Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation: $10 million to the Center for Co-Clinical Trials and the Translational Research Continuum platforms,
- C.G. Johnson Estate: $10 million,
- The Cullen Trust for Health Care: $2 million to the Center for Co-Clinical Trials and the Translational Research Continuum platforms,
- Mr. and Mrs. William J. Kyte: $2 million to the lung cancer moon shot, and
- The John G. and Marie Stella Kenedy Memorial Foundation: $1.5 million.
The Moon Shots Program aims to dramatically reduce deaths initially from:
- acute myeloid leukemia and myelodysplastic syndrome
- chronic lymphocytic leukemia
- lung cancer
- prostate cancer
- triple-negative breast and ovarian cancers
Each moon shot will receive funds and other resources to pursue innovative projects prioritized for greatest patient impact. Specialized platforms will provide infrastructure, technologies or processes that will support all of the moon shots. The goal is to ultimately apply knowledge gained from this process to all cancers.